Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL232286 | 1.00 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Hydrogen Sulfide SCHEMBL11572294 | 0.98 | RNPEP (0.50) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Hydrogen Sulfide SCHEMBL1498068 | 0.98 | RNPEP (0.50) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Hydrogen Sulfide SCHEMBL1498065 | 0.98 | RNPEP (0.50) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL3348587 | 0.98 | RNPEP (0.50) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL7204481 | 0.98 | RNPEP (0.50) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Iodide SCHEMBL3660485 | 0.96 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Iodide SCHEMBL3660488 | 0.96 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Bromide SCHEMBL1498083 | 0.96 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Water SCHEMBL7531314 | 0.96 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171739-A1 | PROCESS FOR GENERATING THERAPEUTIC COMPOSITIONS OF ENGINEERED CELLS | JUNO THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-12258580-B2 | Process for generating therapeutic compositions of engineered cells | JUNO THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | claimed |
| EP-4512823-A2 | PROCESS FOR GENERATING THERAPEUTIC COMPOSITIONS OF ENGINEERED CELLS | Juno Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| EP-2209390-A1 | COMPLEX PRODUCT WITH ADVANCED ASSIMILATION EFFICACY FOR HUMANS AND ITS UTILIZATION | Ficsur, Tibor (HU) | 2010-07-28 | — | — | EP | claimed |
| WO-2009040590-A1 | COMPLEX PRODUCT WITH ADVANCED ASSIMILATION EFFICACY FOR HUMANS AND ITS UTILIZATION | FICSUR TIBOR (HU) | 2009-04-02 | — | — | WO | claimed |
| US-20070014860-A1 | Treatment of esophagitis | ENDO PHARMACEUTICALS COLORADO, INC. | 2007-01-18 | — | — | US | claimed |
| US-20070014861-A1 | Treatment of proctitis | ENDO PHARMACEUTICALS COLORADO, INC. | 2007-01-18 | — | — | US | claimed |
| EP-1343492-B1 | TREATMENT OF MUCOSITIS | RXKINETIX INC (US) | 2006-02-01 | — | — | EP | claimed |
| US-20040141949-A1 | Treatment of mucositis | ENDO PHARMACEUTICALS COLORADO, INC. | 2004-07-22 | — | — | US | claimed |
| EP-1343492-A4 | TREATMENT OF MUCOSITIS | RXKINETIX INC (US) | 2004-05-06 | — | — | EP | claimed |
| US-6685917-B2 | FOR THERAPY OF ORAL MUCOSITIS, ESOPHAGITIS, CYSTITIS, SINUSITIS, ASTHMA, COLITIS, GERD, PROCTITIS, STOMATITIS, CELIAC DISEASE, INFLAMMATORY BOWEL DISEASE, AND CROHN'S DISEASE | RXKINETIX, INC. | 2004-02-03 | — | — | US | claimed |
| EP-1343492-A2 | TREATMENT OF MUCOSITIS | Rxkinetix, Inc. (US) | 2003-09-17 | — | — | EP | claimed |
| US-20020119104-A1 | For therapy of oral mucositis, esophagitis, cystitis, sinusitis, asthma, colitis, GERD, proctitis, stomatitis, celiac disease, inflammatory bowel disease, and Crohn's disease | ENDO PHARMACEUTICALS INC. | 2002-08-29 | — | — | US | claimed |
| WO-2002041837-A2 | TREATMENT OF MUCOSITIS | RXKINETIX, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-6146661-A | WHICH CONTAINS ERYTHRITOL AND OPTIONALLY ANOTHER SUGAR ALCOHOL, WITH A DISSOLUTION ENDOTHERM OF 20 CAL OR MORE PER GRAM OF GASTROINTESTINAL DRUG, AND GASTROINTESTINAL DRUG SUCH AS SUCRALFATE; ORAL ADMINISTRATION WITHOUT WATER OR BAD TASTE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-11-14 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0858801-A1 | CHEWABLE TABLET | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-08-19 | — | — | EP | claimed |
| WO-1994005280-A1 | COMPOSITIONS CONTAINING DIMETHYLSULPHOXIDE AND A SULPHYDRYL GROUP RELEASING AGENT | SALIM AWS SHAKIR MUSTAFA (GB) | 1994-03-17 | — | — | WO | claimed |
| US-4959369-A | S-METHYL SUBSTITUTED SULFONIUM DERIVATIVE OF METHIONINE AND CYSTEINE | SALIM AWS S M (GB) | 1990-09-25 | — | — | US | claimed |
| US-3960661-A | MUTANT BACILLUS SUBTILIS REQUIRING ADENINE FOR GROWTH | AJINOMOTO CO., INC. (JA) | 1976-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014860-A1 | Treatment of esophagitis | PGA5, GSTK1, EPX | GAA 157/4885CA2 2051/4885RNPEP 206/4885 |
| US-20070014861-A1 | Treatment of proctitis | PTGES, PTGES3, PTGES2 | GAA 942/4885CA2 2925/4885RNPEP 215/4885 |
| US-20020119104-A1 | For therapy of oral mucositis, esophagitis, cystitis, sinusitis, asthma, colitis, GERD, proctitis, stomatitis, celiac disease, inflammatory bowel disease, and Crohn's disease | CFTR, HRH2, SI | GAA 17/4885CA2 373/4885RNPEP 1047/4885 |
| US-20040141949-A1 | Treatment of mucositis | MUC1, KRT18, FUT6 | GAA 348/4885CA2 3709/4885RNPEP 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.